曲伏前列素与布林佐胺治疗开角型青光眼或高眼压症的临床研究

目的:研究曲伏前列素与布林佐胺联合治疗原发性开角型青光眼(primary open angle glaucoma,POAG)、高眼压症(ocular hypertension,OHT)及抗青光眼术后高眼压的降眼压疗效及安全性。方法:将48例52眼POAG,OHT,抗青光眼术后高眼压的患者纳入为期2mo的前瞻性、单向性、开放性研究。经药物洗脱期测量眼压基线值。用药后2,4,8,12wk测量眼压、视力、视野,观察眼部症状、体征及全身副作用。计算12wk时眼压≤17mmHg患者百分比。结果:患者基线眼压28.08±2.50mmHg,4次随访眼压(17.12±1.42,16.71±1.55,16.13±1.52,16.12±1.49)mmHg,眼压下降均值10.35mmHg,最大下降率45%。用药后眼压与基线眼压比较差值有非常显著意义(P<0.01),用药12wk时,眼压≤17mmHg的患者占64%。常见的不良反应是结膜充血,偶见轻微烧灼感,轻度味觉异常等,对角膜、泪膜、视力、视野、血压、心率均未影响。结论:曲伏前列素与布林佐胺联合应用降眼压的效果明显,安全性好。联合用药,眼压≤17mmHg患者所占百分比显著。

Clinical research on treatment of travoprost combined with brinzolamide for primary open angle glaucoma or ocular hypertension

AIM:To study the therapeutic effect and safty of travoprost combined with brinzolamide for primary open angle glaucoma(POAG),ocular hypertension (OHT) and high intraocular pressure after anti-glaucoma surgery.·METHODS: Forty-eight cases (52 eyes) with POAG,OHT and high intraocular pressure after anti-glaucoma surgery were subsumed to make a forward-looking,one-way and open study for 2 months. Baseline value of intraocular pressure (IOP) was measured after wash-out period. Then measured IOP,visual acuity and visual field,observed symptoms and signs of eyes and systemic side effects at 2,4,8,12 weeks after treatment. The percentage of patients with IOP≤17mmHg was also counted. ·RESULTS: IOP Baseline value was 28.08±2.50mmHg,In 4 follow-up times,IOP was 17.12±1.42,16.71±1.55,16.13±1.52 and 16.12±1.49mmHg respectively. The mean decrease was 10.35mmHg and the maximum of decreasing rate was 45%. The differences between IOP after treatment and IOP baseline value were statistically significant (P<0.01). The percentage of patients with IOP≤17mmHg was 64%. Common adverse reactions were conjunctival hyperemia,slight burning sensation,mild parageusia and so on,but did not affect cornea,tear film,visual acuity,visual field,blood pressure and heart rate.·CONCLUSION: The therapeutic effect and safty of travoprost combined with brinzolamide to reduce IOP were in evidence.